Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'.

Acta psychiatrica Scandinavica·2012
Same author

Syncytial variant of nodular sclerosing Hodgkin lymphoma.

Lymphology·1999
Same author

Kimura's disease: a case report and literature review.

Journal of surgical oncology·1999
Same author

Association of acute colonic pseudo-obstruction (Ogilvie's syndrome) with herpes zoster.

The American surgeon·1990
Same author

Acute abdomen in drug addicts: think of blunt trauma.

The American journal of gastroenterology·1990
Same author

Upper gastrointestinal series. Should it be done routinely prior to electric cholecystectomy?

New York state journal of medicine·1980

Related Experiment Video

Updated: May 28, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Reason for clozapine cessation.

N B Pai1, S C Vella

  • 1Illawarra Health Medical Research Institute, University of Wollongong, New South Wales, Australia. nagesh@uow.edu.au

Acta Psychiatrica Scandinavica
|October 25, 2011
PubMed
Summary
This summary is machine-generated.

Many patients with refractory schizophrenia stop taking clozapine due to non-compliance or personal decisions, often within six months. Understanding these reasons is key to improving treatment adherence for schizophrenia patients.

Related Experiment Videos

Last Updated: May 28, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Treatment-resistant schizophrenia affects approximately 30% of individuals diagnosed with the condition.
  • Clozapine is the established gold-standard treatment for refractory schizophrenia.
  • A significant proportion of patients discontinue clozapine therapy, necessitating an investigation into cessation motives.

Purpose of the Study:

  • To explore the primary reasons behind patient cessation of clozapine therapy.
  • To identify specific patient-driven and medical factors contributing to treatment discontinuation.

Main Methods:

  • A retrospective review of 151 patients with schizophrenia or schizo-affective disorder who had ceased clozapine treatment.
  • Categorization of cessation motives into non-compliance, own decision, medical reasons, poor response, and other.
  • Further sub-categorization of medical reasons, including cardiac complications, neutropenia, fevers, other side effects, and pregnancy.

Main Results:

  • The predominant reasons for clozapine cessation were non-compliance and patients' own decisions.
  • Approximately 50% of patients ceased treatment within six months or less.
  • Medical reasons accounted for 17% of cessations, with 'other side effects' and 'neutropenia' being the most frequent specific causes.

Conclusions:

  • Further research is needed to understand the underlying reasons for patient non-compliance and self-initiated treatment cessation.
  • Developing targeted strategies to enhance adherence is crucial, particularly for patients who discontinue clozapine due to non-compliance or personal decisions.